enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Valbenazine - Wikipedia

   en.wikipedia.org/wiki/Valbenazine

   Valbenazine, sold under the brand name Ingrezza, is a medication used to treat tardive dyskinesia. [1] It acts as a vesicular monoamine transporter 2 (VMAT2) inhibitor . [ 2 ]

3. Neurocrine Biosciences Reports Mixed Q4 - AOL

   www.aol.com/finance/neurocrine-biosciences...

   Ingrezza continued to perform well in Q4, with net product sales reaching $615 million, marking a 23% year-over-year increase. This growth was primarily due to high patient demand and improved ...

4. US FDA approves Neurocrine Biosciences' movement disorder ...

   www.aol.com/news/neurocrine-biosciences-hunting...

   The U.S. Food and Drug Administration (FDA) has approved the granule formulation of Neurocrine Biosciences' Ingrezza drug to treat movement disorders associated with Huntington's disease (HD), the ...

5. Neurocrine Biosciences - Wikipedia

   en.wikipedia.org/wiki/Neurocrine_Biosciences

   In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD). [ 4 ] The company is also developing treatments that are in various stages of clinical research for Parkinson's disease , Tourette syndrome , and congenital adrenal hyperplasia [ 5 ] and with a partner for endometriosis and ...

6. Why Is Neurocrine Biosciences Stock Trading Lower On Friday?

   www.aol.com/why-neurocrine-biosciences-stock...

   Ingrezza fourth quarter and fiscal 2024 net product sales were $615 million and $2.3 billion, respectively. ... HC Wainwright analyst Andrew Fein maintains Neurocrine Biosciences with a Buy and ...

7. Over-the-counter drug - Wikipedia

   en.wikipedia.org/wiki/Over-the-counter_drug

   Over-the-counter (OTC) drugs are medicines sold directly to a consumer without a requirement for a prescription from a healthcare professional, [1] as opposed to prescription drugs, which may be supplied only to consumers possessing a valid prescription.

8. Deutetrabenazine - Wikipedia

   en.wikipedia.org/wiki/Deutetrabenazine

   A Lancet study published on 28 June 2017 carried out a review between 29 October 2014 and 19 August 2016 where 298 patients were randomly assigned to receive at least one of the following: one dose of placebo per day, one dose of deutetrabenazine 12 mg/day, one dose of deutetrabenazine 24 mg/day, or one dose of deutetrabenazine 36 mg/day.

9. Free the Meds: 5 Drugs You Should Be Able To Buy Over the Counter

   www.aol.com/news/free-meds-5-drugs-able...

   The post Free the Meds: 5 Drugs You Should Be Able To Buy Over the Counter appeared first on Reason.com. Show comments. Advertisement. Advertisement. In Other News. Entertainment. Entertainment.